Growing understanding of the etiopathogenesis of the major forms of atypical parkinsonism has led to the testing of many potential disease modifying interventions. Irene Litvan, MD, FAAN, FANA, University of California San Diego, La Jolla, CA, discusses research looking into methods of tackling disease progression in corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP). Few trials are ongoing in the CBD space. PSP is an area of more progress, with several agents under investigation. These include antibodies that can scavenge abnormal proteins in the brain and antisense oligonucleotides and small molecules that aim to inhibit the production of abnormal proteins. This interview took place during the 2021 International Congress of Parkinson’s Disease and Movement Disorders.
Dr Litvan’s research is supported by the National Institutes of Health grants: 2R01AG038791-06A, U01NS100610, U01NS80818, R25NS098999; U19 AG063911-1 and 1R21NS114764-01A1; the Michael J Fox Foundation, Parkinson Foundation, Lewy Body Association, CurePSP, Roche, Abbvie, Biogen, Centogene. EIP-Pharma, Biohaven Pharmaceuticals, Novartis, Brain Neurotherapy Bio and United Biopharma SRL – UCB. She was a member of the Scientific Advisory Board of Lundbeck and is a Scientific advisor for Amydis and Rossy Center for Progressive Supranuclear Palsy University of Toronto. She receives her salary from the University of California San Diego and as Chief Editor of Frontiers in Neurology.